2013 Annual Meeting of the American Association for the Study of Liver Diseases*

November 1-5, 2013; Washington, DC
CCO is the official provider of online conference coverage of The Liver Meeting 2013, through Capsule Summaries, expert faculty analysis of the most important data, and downloadable slides

Highlights From AASLD 2013: Other Highlights and Special Populations


Sofosbuvir/RBV-based therapy yielded marked clinical improvement and/or disease stabilization in 75% of patients and was well tolerated; however, serious adverse events were common in this very sick patient population.

Released: November 4, 2013

Meta-analysis of data from 10 patient cohort studies found that the ongoing risk of developing HCC for patients with HCV-induced cirrhosis and who achieve SVR is approximately 1% with the risk increasing with advanced age, more severe liver disease, or diabetes.

Released: November 6, 2013

In a phase III trial, 76% of patients with genotype 1 HCV achieved SVR12 with 24 weeks of therapy; 88% of patients with genotype 2 HCV and 67% with genotype 3 HCV achieved SVR12 with 12 weeks of therapy.

Released: November 6, 2013

Patients who achieved > 30 consecutive days with HCV RNA target not detected before transplantation were highly likely to remain free of HCV recurrence 12 weeks after transplantation.

Released: November 7, 2013

Patients experiencing recurrence of genotype 1 HCV infections following liver transplantation achieved SVR12 with boceprevir plus pegIFN/RBV of 51% and 41% achieved SVR12 with telaprevir plus pegIFN/RBV, but ≥ 50% discontinued therapy due to adverse events or virologic failure.

Released: November 6, 2013

The HBV reactivation rate for patients anti-HBsAg negative, anti-HBcAg positive is 24.2% when they are treated with rituximab-based chemotherapy for hematologic malignancies.

Released: November 7, 2013

A total of 72% of HCV/HIV-coinfected patients achieved undetectable HCV RNA after 12 weeks of treatment with telaprevir plus pegIFN/RBV and 99% maintained HIV-1 RNA < 50 copies/mL while on therapy.

Released: November 5, 2013

The majority of patients in the registry who received telaprevir- or boceprevir-based triple therapy had a previous nonresponse to treatment (62%), and most received telaprevir vs boceprevir (76% vs 24%).

Released: November 5, 2013

Pilot study finds 24-week treatment leads to HCV RNA negativity in all patients by Week 4, which is sustained throughout therapy; SVR4 rate of 77% at interim analysis.

Released: November 5, 2013

In this large cohort of patients from 2 earlier studies with long-term follow-up, fibrosis stage was found to be more accurate than NAS for predicting overall and disease-specific mortality.

Released: November 8, 2013

In this pilot study, preliminary data reveal disproportionately high HCV prevalence rates among males and the uninsured/underinsured.

Released: November 8, 2013
Jointly sponsored by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)

Produced in collaboration with
Educational grant provided by:
Boehringer Ingelheim Pharmaceuticals, Inc.
Gilead Sciences
Janssen Therapeutics

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?